Novel insights into the systemic treatment of lung cancer malignant pleural effusion

Clin Respir J. 2019 Mar;13(3):131-138. doi: 10.1111/crj.13005.

Abstract

Lung cancer is the most common fatal malignancy worldwide. Approximately 75% of non-small-cell lung cancer (NSCLC) patients are diagnosed at an advanced or a metastatic stage. Since 2007, NSCLC patients with malignant pleural effusion (MPE) are staged as M1 disease. During the last decades, chemotherapeutic agents failed to offer a significant improvement of survival in patients with metastatic disease. The current review aims to summarize the actual situation of the recently developed therapies in patients with lung cancer and MPE.

Keywords: immunotherapy; lung cancer; malignant pleural effusion; pleural disease; targeted therapy; treatment.

Publication types

  • Review

MeSH terms

  • Anaplastic Lymphoma Kinase / genetics
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / complications
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Clinical Trials as Topic
  • Female
  • Humans
  • Lung Neoplasms / complications
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Male
  • Mutation
  • Neoplasm Staging
  • Pleural Effusion, Malignant / drug therapy*
  • Pleural Effusion, Malignant / genetics
  • Pleural Effusion, Malignant / pathology

Substances

  • Antineoplastic Agents
  • ALK protein, human
  • Anaplastic Lymphoma Kinase